Featured Insight
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
Poster Presentation: San Antonio Breast Cancer Symposium (SABCS) 2023
Gilead Sciences, Inc. will present new data at the San Antonio Breast Cancer Symposium (SABCS) 2023 supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients. Precision's research with Gilead Sciences on "Understanding Clinical Meaningfulness in Metastatic Breast Cancer Treatment Decision-Making" will be presented during Poster Session 1: Poster # PO1-10-06 on Wednesday, Dec. 6 at 12:00 PM. Co-authored by Meaghan Roach, Rozanne Wilson, Suepattra May-Slater, Melissa Maravic and Emily Freeman.
Short Courses: ISPOR EU 2023
Precision will be at ISPOR Europe November 12-15, 2023. Don't miss our two Short Courses.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Webinar: Quantifying Health Equity Impact of Innovative Health Care Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join PRECISIONheor for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
On-Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Insulin imports fail to meet many countries’ needs
Despite 100-year since its discovery, insulin – a life-saving medicine – remains inaccessible to millions around the world, owing to limited availability and high cost. Insulin is manufactured in just 20 countries worldwide, leaving all the other countries dependent on imports to meet the needs of their patients with diabetes.
Analytical Estimation of Data-Motivated Time-Dependent Disease Transmission Rate: An Application to Ebola and Selected Public Health Problems
Quantification of temporal transmission potential of an infectious disease has been a challenge. Most mathematical models assume that the transmission rate of an infectious disease either does not vary over time or change in fixed pre-determined adhoc ways.
A Solution Tool for Clinical Challenges in the Prognosis of Liver Injury
Several clinical scoring systems have gradually emerged for liver injury diagnosis, but certain serious inherent deficiencies currently limit their predictive value. Precision's Anuj Mubayi and co-author Aditi Ghosh report on their first of its kind study to use mathematical modeling to provide an accurate novel prognosis method to improve tools for diagnosis and clinical management of drug-induced acute liver injury and heart-attack-influenced ischaemic hepatitis liver injury.
What does it mean to be patient centered in health economics?
With drug pricing becoming a hot-button issue in recent years, the spotlight has focused on cost effectiveness models as a means of reducing health care spending, and pharmaceutical spending in particular. Precision's Jacquelyn Chou argues that the current cost effectiveness model is too narrow, and identifies additional elements of value that should be included to provide a better voice for patients in the science, rather than serving as a cost-containment tool.
On-Demand Webinar: Methodological Borrowing versus Conceptual Blending: Reengineering Health Economics Processes with Modeling and Simulations
Join us for "Methodological Borrowing versus Conceptual Blending: Reengineering Health Economics Processes with Modeling and Simulations," Featuring PRECISIONheor's Ross Maclean and Anuj Mubayi.
PRECISIONheor Featured CNS/Neuro Publications
Want a glimpse at some of the groundbreaking work PRECISIONheor experts have recently contributed to in the CNS/Neuro Space to help get life-saving treatments in the hands of patients that need them the most?
Making life-saving medical treatments more affordable
Despite efforts to accelerate FDA evaluation of drug safety and efficacy, uptake of many new therapies has been much slower than expected. Why the lag?
Chou and Stillerman Talk Value Assessments in MedAd News
In a new MedAd News feature article on the influence of value assessments, Precision Xtract’s Jacki Chou and Zac Stillerman provide their insights on the growing influence of ICER, and how manufacturers can be more proactive in shaping favorable assessments of their new treatments.
CBO says proposed rule to kill rebates will increase spending by $177 billion
Precision experts Jeremy Schafer, Jacki Chou, and Harry G. Schiavi join other industry leaders in discussing the potential repercussions of the rule.
Precision’s Baumgardner warns HIV advances could be negatively impacted by changes to Medicare Part D rule
HHS’ proposed changes to Medicare Part D loosening government restrictions on 4 protected drug classes directly imperils those with HIV who have Medicare as their source of health coverage,
ICER will examine drugs with unsupported price increases
The Institute for Clinical and Economic Review (ICER) says it will create a series of so-called Unsupported Price Increase (UPI) reports that will examine whether price increases are justified.
